-
1 Comment
NanoCarrier Co., Ltd is currently in a long term downtrend where the price is trading 12.9% below its 200 day moving average.
From a valuation standpoint, the stock is 95.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 57.9.
NanoCarrier Co., Ltd's total revenue sank by 60.6% to $56M since the same quarter in the previous year.
Its net income has dropped by 53.2% to $-369M since the same quarter in the previous year.
Based on the above factors, NanoCarrier Co., Ltd gets an overall score of 1/5.
| Exchange | F |
|---|---|
| CurrencyCode | EUR |
| ISIN | JP3651120002 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 57M |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Beta | 0.35 |
| Dividend Yield | None |
NANO MRNA Co.,Ltd. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. The company's pipeline products include RUNX1 (mRNA) for the treatment in the area of tissue generation and vaccines; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma multiforme. In addition, it offers Complex, an antibacterial ear drops; cosmetic raw material, and platelet-rich therapy. The company was formerly known as NanoCarrier Co., Ltd. and changed its name to NANO MRNA Co.,Ltd. in June 2023. NANO MRNA Co.,Ltd. was incorporated in 1996 and is headquartered in Tokyo, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 3NQ.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
